PD L1 News and Research

RSS
Immunotherapy drug approved by FDA as first-line treatment for non-small cell lung cancer

Immunotherapy drug approved by FDA as first-line treatment for non-small cell lung cancer

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Study finds neoadjuvant immunotherapy safe, viable for early lung cancer patients before surgery

Study finds neoadjuvant immunotherapy safe, viable for early lung cancer patients before surgery

Research shows how new ovarian cancer treatment could help boost anti-tumor immunity

Research shows how new ovarian cancer treatment could help boost anti-tumor immunity

Yale researchers compare efficacy of four PD-L1 assay tests

Yale researchers compare efficacy of four PD-L1 assay tests

BET inhibitors could be powerful new therapeutic strategy for ovarian cancer

BET inhibitors could be powerful new therapeutic strategy for ovarian cancer

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

New clinical trial to examine safety of checkpoint inhibitor in pediatric cancer patients

New clinical trial to examine safety of checkpoint inhibitor in pediatric cancer patients

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

PD-1-responsive T cells may offer clues to design more effective drugs for cancer

PD-1-responsive T cells may offer clues to design more effective drugs for cancer

Roche announces FDA approval of  new VENTANA PD-L1 assay

Roche announces FDA approval of new VENTANA PD-L1 assay

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

Immunotherapy drugs given after chemotherapy may benefit ovarian cancer patients

Immunotherapy drugs given after chemotherapy may benefit ovarian cancer patients

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

Study opens up new strategy to make immunotherapy more effective for different cancer types

Study opens up new strategy to make immunotherapy more effective for different cancer types

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

Nivolumab drug shows better response rate in metastatic bladder cancer patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

Combination of chemotherapy and immunotherapy may be effective against ovarian cancer

Combination of chemotherapy and immunotherapy may be effective against ovarian cancer

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

Tecentriq drug gets FDA approval to treat urothelial carcinoma

Tecentriq drug gets FDA approval to treat urothelial carcinoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.